Udenafil

Udenafil, an oral therapy for the treatment of erectile dysfunction (ED), is a pyrazolopyrimidinone class and a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) of the corpus cavernosum, which induce potent penile erection.

Udenafil has an optimal duration of action of up to 8-12 hours. Clinical pharmacodynamic study showed that the time to maximum concentration (T_max) and half-life (T_I/2) of udenafil are approximately 1 hour and 10-12 hours, respectively. The ability to maintain an erection sufficient for a successful intercourse (SEP3) at 8-12 hours after taking udenafil (100 mg) was significantly superior to placebo in phase III study.

The efficacy and safety of udenafil are satisfactory in all the phase I, II, and III studies. Udenafil is an oral therapy for the treatment of ED, which completed the clinical trial processes in Korea. The major adverse events are flushing, nasal congestion, headache, and dyspepsia. However, most adverse events were temporal and mild in severity.

Moreover, these adverse events soon resolved without treatment.

Udenafil does not inhibit phosphodiesterase type 11 (PDE11) (>3,000-fold selectivity) and adverse effects such as myalgia, back pain have not been reported.